Elsevier Inc.

SHERPA: Unknown

People

  1. Berger
    Berger
  2. Solit
    Solit
  3. Iyer
    Iyer
  4. Schultz
    Schultz
  5. Al-Ahmadie
    Al-Ahmadie
  6. Bajorin
    Bajorin
  7. Bochner
    Bochner
  8. Drilon
    Drilon
  9. Gao
    Gao
  10. Haque
    Haque

Groups

  1. GSK Faculty (7)
  2. Human Oncology and Pathogenesis Program (7)
  3. Department of Medicine (4)
  4. Solid Tumor Oncology Division (4)
  5. Genitourinary Oncology Service (3)
  6. Surgery (3)
  7. Center for Hematologic Malignancies (2)
  8. Center for Pancreatic Cancer Research (2)
  9. Computational Oncology Service (2)
  10. Epidemiology and Biostatistics (2)
Search Within
  1. "European Journal of Cancer"
  2. "Michael Berger"
Formats
  1. Meeting Abstract (7)
Groups
  1. GSK Faculty (7)
  2. Human Oncology and Pathogenesis Program (7)
  3. Department of Medicine (4)
  4. Solid Tumor Oncology Division (4)
  5. Genitourinary Oncology Service (3)
  6. Surgery (3)

More Groups

People
  1. Michael Berger (7)
  2. David Solit (3)
  3. Gopakumar Iyer (2)
  4. Helen Won (2)
  5. Hikmat Al-Ahmadie (2)
  6. Jose Baselga (2)

More People

Years
  1. 2022 (1)
  2. 2018 (1)
  3. 2016 (1)
  4. 2015 (1)
  5. 2014 (2)
  6. 2013 (1)
Publications
  1. European Journal of Cancer (7)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HER2 as a therapeutic target in bladder cancer
    Meeting Abstract

    Chen, Z.; Tang, X.; Christin, J. R.; Gao, S. P.; Chu, C. E.; Berger, M. F.; Schultz, N. D.; Shen, M. M.; Al-Ahmadie, H. A.; Iyer, G.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Characterization of the genetic landscape of low mutation burden malignancies through multi-parallel genomic and immunologic analysis
    Meeting Abstract

    Trippett, T.; Berger, M.; Narendran, A.; Lyden, D.; Kovalchuk, O.; Bodour, S.; Laquaglia, M.; Ambati, S.; Schultz, N.; Roehrl, M.
    European Journal of Cancer (2018)

    Fulltext@MSK | Save
  • Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: From bench to bedside
    Meeting Abstract

    Ho, A.; Wei, G.; Maneval, E. C.; Esquibel, V.; Berger, M. F.; Haque, S.; Patel, R.; Walsh, C.; Hornby, Z.; Multani, P.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Assessment of genomic alterations in bladder adenocarcinoma and urachal adenocarcinoma
    Meeting Abstract

    Jordan, E.; Won, H.; Toubaji, A.; Bagrodia, A.; Desai, N.; Bajorin, D.; Rosenberg, J.; Bochner, B.; Kim, W.; Berger, M.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • AKT3 activation mediates resistance to HER2-targeted therapies in HER2-amplified breast cancer
    Meeting Abstract

    Carmona Sanz, F.; Montemurro, F.; Rossi, V.; Verma, C.; Berger, M.; Baselga, J.; Scaltriti, M.
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • Loss of PTEN leads to acquired resistance to the PI3Ka inhibitor BYL719: A case of convergent evolution under selective therapeutic pressure
    Meeting Abstract

    Castel, P.; Juric, D.; Griffith, M.; Griffith, O. L.; Won, H. H.; Ainscough, B.; Ellis, H.; Ebbesen, S.; Gopakumar, I.; Quadt, C.; more...
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • Massively parallel sequencing analysis of clinical samples: Challenges and opportunities
    Meeting Abstract

    Berger, M.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save